Building on its recent €3.5 million (~USD $4 million) seed round, Garland Surgical is launching preparations for a larger Series A financing to fund clinical studies and subsequently support the commercialization of its TriActiv Hip system (previously known as MaltaHip).
The seed financing will be used to complete final design and verification of the TriActiv Hip system in line with regulatory requirements and to strengthen quality and regulatory infrastructure in preparation for EU and U.S. regulatory submissions. Garland will also invest in team development, surgeon engagement, usability work, and planning of first‑in‑human clinical trials to support its evidence‑generation roadmap.
TriActiv Hip introduces a different triaxial architecture that is engineered to unlock a wider, more natural movement envelope while maintaining control throughout the range of motion. By reshaping how physical forces are transmitted and constrained in the joint, the TriActiv system is intended to cut the risk of dislocation, reduce edge‑loading and wear, and support long‑term mechanical integrity. This combination of motion, control and durability is designed to change how surgeons think about primary and complex hip replacement, to expand treatment options for higher‑risk and higher‑demand patients, and to create a new benchmark for lifetime hip performance.
Building on its recent €3.5 million (~USD $4 million) seed round, Garland Surgical is launching preparations for a larger Series A financing to fund clinical studies and subsequently support the commercialization of its TriActiv Hip system (previously known as MaltaHip).
The seed financing will be used to complete final design and verification...
Building on its recent €3.5 million (~USD $4 million) seed round, Garland Surgical is launching preparations for a larger Series A financing to fund clinical studies and subsequently support the commercialization of its TriActiv Hip system (previously known as MaltaHip).
The seed financing will be used to complete final design and verification of the TriActiv Hip system in line with regulatory requirements and to strengthen quality and regulatory infrastructure in preparation for EU and U.S. regulatory submissions. Garland will also invest in team development, surgeon engagement, usability work, and planning of first‑in‑human clinical trials to support its evidence‑generation roadmap.
TriActiv Hip introduces a different triaxial architecture that is engineered to unlock a wider, more natural movement envelope while maintaining control throughout the range of motion. By reshaping how physical forces are transmitted and constrained in the joint, the TriActiv system is intended to cut the risk of dislocation, reduce edge‑loading and wear, and support long‑term mechanical integrity. This combination of motion, control and durability is designed to change how surgeons think about primary and complex hip replacement, to expand treatment options for higher‑risk and higher‑demand patients, and to create a new benchmark for lifetime hip performance.
Copy to clipboard 
